Physician profile
Jaurel Harley
NPI 1497117410
$693.43
in general payments reported to CMS, 2019-2025
11 companies · $222 in 2025
The $222 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.56 · 2021: $97.25 · 2022: $20.49 · 2023: $198 · 2024: $128 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $197.88 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $176.95 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $75.93 | 2021 | |
| Corium, LLC | $62.56 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $56.02 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $29.94 | 2023 | Flumist Quadrivalent |
| Sobi, INC | $24.38 | 2023 | |
| Nestle Healthcare Nutrition INC. | $21.32 | 2021 | |
| Cranial Technologies, INC | $19.56 | 2025 | Doc Band |
| Cipher Pharmaceuticals US LLC | $14.97 | 2025 | Natroba, Spinosad |
| Amneal Pharmaceuticals LLC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaurel Harley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.